Table 5.
SCARS-guided cancer stemness matrix of diagnostic and therapeutic targets comprising of 237 SCARS-down-regulated and 141 SCARS-activated cancer driver genes mapped to 28 cancer types.
| Cancer Type | Number of SCARS-silenced cancer driver genes | Number of SCARS-activated cancer driver genes |
|---|---|---|
| Adenoid Cystic | 7 | 4 |
| Bladder | 30 | 16 |
| Blood | 25 | 22 |
| Brain | 28 | 16 |
| Breast | 28 | 17 |
| Cervix | 12 | 8 |
| Cholangiocarcinoma | 8 | 4 |
| Colorectal | 16 | 12 |
| Endometrium | 30 | 20 |
| Gastroesophageal | 37 | 26 |
| Head & Neck | 19 | 6 |
| Kidney Clear | 8 | 5 |
| Kidney Non-Clear | 14 | 6 |
| Liver | 18 | 10 |
| Lung AD | 15 | 9 |
| Lung SC | 7 | 3 |
| Lymph | 36 | 25 |
| Ovarian | 4 | 2 |
| Pancreas | 22 | 17 |
| Pheochromocytoma | 5 | 3 |
| Pleura | 9 | 0 |
| Prostate | 19 | 11 |
| Sarcoma | 6 | 3 |
| Skin | 21 | 13 |
| Testicular Germ Cell | 11 | 8 |
| Thymus | 7 | 2 |
| Thyroid | 8 | 9 |
| Uveal Melanoma | 2 | 1 |
| Number of actionable cancer therapy-guiding nodes defined by the SCARS stemness matrix mapped to connect Cancer Driver Genes/Cancer Type/Regulatory SCARS | 1,365 | 834 |
AD, adenocarcinoma; SC, small cell carcinoma. Bold values report total number of actionable cancer therapy-guiding nodes defined by the SCARS stemness matrix.